Edwards Hellen McKinnon, Noer Mette Calundann, Sperling Cecilie Dyg, Nguyen-Nielsen Mary, Lundvall Lene, Christensen Ib Jarle, Høgdall Claus
a The Department of Obstetrics and Gynaecology , University of Copenhagen Herlev Hospital , Herlev , Denmark ;
b Department of Gynecology , Juliane Marie Centret, Rigshospitalet, University of Copenhagen , Copenhagen , Denmark ;
Acta Oncol. 2016 Jun;55 Suppl 2:36-43. doi: 10.1080/0284186X.2016.1182641. Epub 2016 Jun 29.
Ovarian cancer has a high mortality rate, especially in Denmark where mortality rates have been reported higher than in adjacent countries with similar demographics. This study therefore examined recent survival and mortality among Danish ovarian cancer patients over an 18-year study period.
This nationwide registry-based observational study used data from the Danish Gynecology Cancer Database, Danish Pathology Registry, and Danish National Patient Registry. All patients with ovarian cancer diagnosed between 1995 and 2012 were included in the study. The data sources were linked via the patients' personal identification number and the analyses included data on cancer stage, age, survival, surgery status and comorbidity. The computed outcome measures were age-adjusted mortality rates and age-adjusted overall and relative survival rates for one and five years.
We identified 9972 patients diagnosed with ovarian cancer in the period 1995-2012. The absolute one-year mortality rate decreased from 42.8 (CI 40.3-45.6) in 1995-1999 to 28.3 (CI 25.9-30.9) in 2010-2012, and the five-year mortality rate decreased from 28.2 (CI 27.0-29.5) in 1995-1999 to 23.9 (CI 22.9-25.0) in 2005-2009. After stratification by age, comorbidity and cancer stage, the decrease in one-year mortality was most substantial in the 65-74 year old age group 41.1 (CI 38.8-43.5) to 26.5 (CI 24.4-28.7) and for stage III 39.1 (CI 35.1-43.6) to 22.9 (CI 19.9-26.5) and stage IV 91.3 (CI 80.8-103.2) to 41.9 (CI 35.5-49.5). For overall survival, we showed an increase in one-year survival from 68% (CI 66-69%) in 1995-1999 to 76% (CI 74-78%) in 2010-2012 and an increase in five-year survival from 33% (CI 32-35%) in 1995-1999 to 36% (CI 34-38%) in 2005-2009. Relative survival showed similar increases through the period.
Ovarian cancer survival in Denmark has improved substantially from 1995 to 2012, bringing Denmark closer to the standards set by adjacent countries.
卵巢癌死亡率很高，尤其是在丹麦，据报道其死亡率高于人口统计学特征相似的邻国。因此，本研究调查了丹麦卵巢癌患者在18年研究期间的近期生存和死亡情况。
这项基于全国登记处的观察性研究使用了丹麦妇科癌症数据库、丹麦病理登记处和丹麦国家患者登记处的数据。1995年至2012年间诊断出的所有卵巢癌患者均纳入本研究。数据来源通过患者的个人识别号码进行关联，分析包括癌症分期、年龄、生存情况、手术状态和合并症的数据。计算得出的结果指标为年龄调整死亡率以及1年和5年的年龄调整总生存率和相对生存率。
我们确定了1995 - 2012年期间9972例诊断为卵巢癌的患者。1年绝对死亡率从1995 - 1999年的42.8（置信区间40.3 - 45.6）降至2010 - 2012年的28.3（置信区间25.9 - 30.9），5年死亡率从1995 - 1999年的28.2（置信区间27.0 - 29.5）降至2005 - 2009年的23.9（置信区间22.9 - 25.0）。按年龄、合并症和癌症分期分层后，1年死亡率下降幅度最大的是65 - 74岁年龄组，从41.1（置信区间38.8 - 43.5）降至26.5（置信区间24.4 - 28.7），III期从39.1（置信区间35.1 - 43.6）降至22.9（置信区间19.9 - 26.5），IV期从91.3（置信区间80.8 - 103.2）降至41.9（置信区间35.5 - 49.5）。对于总生存率，我们发现1年生存率从1995 - 1999年的68%（置信区间66 - 69%）提高到2010 - 2012年的76%（置信区间74 - 78%），5年生存率从1995 - 1999年的33%（置信区间32 - 35%）提高到2005 - 2009年的36%（置信区间34 - 38%）。在此期间相对生存率也有类似提高。
1995年至2012年丹麦卵巢癌患者的生存率有显著提高，使丹麦更接近邻国设定的标准。
